slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Director’s Report to the National Advisory Council on Drug Abuse PowerPoint Presentation
Download Presentation
Director’s Report to the National Advisory Council on Drug Abuse

Loading in 2 Seconds...

play fullscreen
1 / 42

Director’s Report to the National Advisory Council on Drug Abuse - PowerPoint PPT Presentation


  • 349 Views
  • Uploaded on

Director’s Report to the National Advisory Council on Drug Abuse September 10, 2008 Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities NIDA BUDGET (Thousands) 2006 Actual 2008 Est. 2009 P.B. 2007 Budget

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Director’s Report to the National Advisory Council on Drug Abuse' - jana


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Director’s Report to the

National Advisory Council

on Drug Abuse

September 10, 2008

slide2

Director’s Report to the

National Advisory Council on Drug Abuse

Budget Update

What’s New @ NIH?

Recent NIDA Activities

slide3

NIDA BUDGET

(Thousands)

2006Actual

2008Est.

2009P.B.

2007Budget

Authority

$698,976

$699,168

$301,532

$1,000,700

+0.1%

$700,140

$301,532

$1,001,672

+0.1%

$699,852

$300,162

$1,000,014

NonAIDS

$299,882

AIDS

$998,858

TOTAL

Increase

Over

Prior Year

-0.8%

+0.6%

slide4

What’s New @ NIH?

  • NIH Leadership Forum
  • Sept 4, 2008
  • Early Stage Investigator (< 10 years from degree)
  • Effectiveness Research
systems model suggests 1600 esi s must enter nih workforce to maintain average age

ESI (avg. age 35)

ESI (avg. age 38)

Systems Model Suggests 1600 ESI’s Must Enter NIH Workforce to Maintain Average Age

Average Age of PI Pool Based on Number of New R01 PI's

The average age of the ESI population currently funded is 38

56.0

54.0

52.0

50.0

Age

48.0

Baseline

46.0

44.0

42.0

Age 2006

40.0

1100

1600

2100

2600

Number of New R01 Investigators

nih targets for new investigators
No matter the approach, 1500 is the minimum number of New PIs

To improve demographic profile of the NIH Workforce, more PIs, at earlier career stages, must be added

Setting IC targets

-- Possible options:

- Percent RPG budget

- Success Rate

NIH Targets for New Investigators
rfa 2 epigenomics of human health and disease
RFA 2: Epigenomics of Human Health and Disease

Aging

Development

EPIGENOME

DISEASE

GENOME

Environmental Exposure

Modifiers of Stress

(RFA-RM-08-017) Release/Posted Date: July 16, 2008Application Due Date(s): October 28, 2008

  • Trans IC-led demonstration
  • projects addressing IC related
  • priorities
  • Build on reference epigenomes
  • A total of $8 million in FY 2009
  • has been committed to support this FOA
  • 50/50 RM1.5/IC co-funding, FY09-FY15
  • Determine how the epigenome changes with conditions of aging, development, gender, and environmental exposures
  • Determine how the epigenome changes with diseases or conditions that cross ICs (ie. inflammation, pain, obesity)
slide8

Director’s Report to the

National Advisory Council on Drug Abuse

Budget Update

What’s New @ NIH?

Recent NIDA Activities

slide9

Review Committee:

D. Piomelli, Pharm.D., Ph.D. (Chair)

University of California, Irvine

M.J. Kreek, M.D., Ph.D.

Professor, The Rockefeller University

P. Kalivas, Ph.D.

Medical University of South Carolina

R. Nakamura, Ph.D.

Deputy Director, NIMH

L. Porrino, Ph.D.

Wake Forest University School of Medicine

Scientific Director Administrative Review

Bayview Medical Center

April 17 – 18, 2008

“With respect to the scientific vision of Dr. Hoffer, .. the Committee finds his accomplishments in realizing that vision to be highly commendable.”

Communication and Cooperation

1. Increase transparency of decision-making processes.

2. Increase interactions among IRP scientists.

3. Use tools of social network analysis to enhance

interactions among IRP scientists.

Conducting Human Research on Drug Abuse

4. Improve recruiting for protocols.

5. Improve interactions with the NIH IRB

6. Enhance supervision of contract with Maryland

Psychiatric Research Center.

7. Extend collaborations with other NIH IC

8. Consider alternative venues for clinical research.

Cultural Diversity among IRP Researchers

9. Dr. Hoffer has done a tremendous job at supporting

scientific success of minority researchers within the

IRP … it is important that he continues to maintain a

high level of vigilance on this issue.

slide10

NIDA Prevention Research Review Workgroup

WORK GROUP MEMBERS

CHAIR

Mark T. Greenberg, Ph.D.COUNCIL MEMBERS

Mary Jane Rotheram-Borus, Ph.D.

Marina E. Wolf, Ph.D.

ADDITIONAL SENIOR SCIENTISTS

Anthony Biglan, Ph.D.

Dante Cicchetti, Ph.D.

Phil Fisher, Ph.D.

Marguerita Lightfoot, Ph.D.

Michael Neale, Ph.D.

Hilda Pantin, Ph.D.

Irwin Sandler, Ph.D.

First Meeting Convened on September 8-9, 2008

slide11

NIDA 2008 RETREAT

Promoting Transformational & Innovational Research

June 26-27, 2008

  • Subject Team Workgroups
  • Medications Development
  • Translational Research
  • Promoting Infrastructure Utilization
  • Next Generation of Prevention Research
  • Next Generation of Genetics/Epigenetics Research
  • Increase interactions of researchers from different fields
  • (e.g. statistics + genetics, epidemiology + genetics)
  • Increase utilization of NIH research infrastructure
  • Focus on how to translate basic research findings to treatment strategies
  • (e.g., nicotine findings)
  • Take proactive steps to attract the best people to NIDA
slide12

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide13

Ileana Cristea, Ph.D.

Assistant Professor in the Department of Molecular Biology, Princeton University

Proteomic Tools to Uncover the Role of Chromatin Remodeling in HIV-1

infection

Jerome Groopman, M.D.

Professor of Medicine, Dina and Raphael Recanati Chair at the Harvard Medical School

Chief, Division of Experimental Medicine at the Beth Israel Deaconess Medical Center

Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors

Julio Montaner, M.D.

Professor of Medicine, University of British Columbia; Head, Division of AIDS Canada

Director, British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care

Adjunct Professor, Department of Psychiatry, University of California, San Diego

Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDUs

slide14

NIDA Sponsored Events:

  • A Skills Building-Workshop -- “Drug Abuse & HIV/AIDS
  • Research: Improving Public Health in Latin America”
  • A Satellite Symposium -- “Drug Abuse and HIV/AIDS
  • Interventions: An International Perspective”
  • Extensive Media Coverage including a Press Roundtable
  • and numerous TV, Radio and Newspaper Interviews with
  • Drs. Nora Volkow & Jacques Normand
slide15

Press Coverage Reached an Estimated 50 million

through TV, Radio, Online & Print in the

U.S, Mexico, Central & South America

Press Roundtable

16 Additional TV, Radio

& Magazine Interviews

Live Interview on

CNN Mexico

slide16

Cumulative All-Cause and Non-Accidental Mortality Rate Among Antiretroviral-Naïve Patients Initiating HAART

Wood, E et al., JAMA, pp. 550-554, August 15, 2008.

slide17

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DPMCDA

Wilson Compton, MD, MPE

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide18

Medications Development for

PolydrugAddiction Treatment

(R01–PAS-08-186) (R21--PAS-08-187)

Issued June 26, 2008

Medications Development for

Cannabis-Related Disorders (R01)

(RFA-DA-09-001)

Issued April 23, 2008

Pilot Clinical Trialsof Pharmacotherapies

for Substance Related Disorders (R01)

(RFA-DA-09-005)

Issued June 12, 2008

National Cooperative Drug Discovery &

Development Groups (NCDDDG) for the

Treatment of Mental Disorders, Drug or

Alcohol Addiction (U01/U19)

(PAR-08-238) (with NIMH and NIAAA)

Issued August 14, 2008

slide19

DEVELOPING NEW TOOLS TO

PREVENT AND TREAT ADDICTION:

Vaccine Development on the Horizon

A Congressional Briefing Sponsored by

The FRIENDS OF NIDA

In conjunction with

The Addiction, Treatment and Recovery Caucus

Tuesday, July 29, 2008

slide20

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DESPR

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide21

Reducing Risk Behaviorsby Promoting

Positive Youth Development

(R01-PA-08-241) (R03-PA-08-242) (with NICHD, NCI and NIAAA)

Issued August 15, 2008

Drug AbusePrevention

InterventionResearch

(R01–PA-08-217) (R21--PA-08-218) (R03--PA-08-219

Issued July 25, 2008

Integrating Biobehavioral &

Sociocultural Research to Prevent

HIV Transmissionand Infection

(R01-PA-08-188) (R21-PA-08-189) (with NINR, NIMH and NIAID)

Issued June 30, 2008

slide22

Criminal JusticeDrug Abuse

Treatment Studies 2 (CJ-DATS 2) (U01)

(RFA-DA-09-006)

Issued June 24, 2008

ImprovingEffectiveness of Smoking

CessationInterventions and Programs in

Low Income Adult Populations

(R01-RFA-CA-08-022) (R21-RFA-CA-08023) (with NCI)

Issued June 18, 2008

Economicsof Treatment and Prevention

Services for Drug & Alcohol Abuse

(R01-PA-08-174) (R03-PA-08-172) (R21-PA-08-173) (with NIAAA)

Issued June 6, 2008

nida resource guide sbi
NIDA Resource Guide SBI
  • Targets adult primary care with a key goal of
  • increasing screening for illicit drug abuse
  • Provides a clinician-friendly guide to support
  • screening and brief intervention
  • Strengthens clinicians’ ability to discuss screening
  • results with patients
  • Brief, graphical introduction to screening and brief intervention steps for primary care providers
  • Will be on the NIDA website
  • Recommends the WHO ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test)
future manual development
Future Manual Development

Modify drug categories to emphasize prescription stimulants, sedatives and opioids as separate categories

Finish drafting manual

-- Introduction

-- Appendices

-- Pocket Guide

Review with clinicians

Finalize

Disseminate widely

slide25

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

CCTN

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

Wilson Compton, MD, MPE

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide26

CTSA

Clinical & Translational

Science Awards

Translating Discoveries to Medical Practice

38 Members

slide27

NIDA Interactions with CTSAs

  • Mayo CTSA PI, Bob Rizza, visited NIDA and met with NIDA senior staff on 4/17/08

NIDA Director visited Mayo CTSA 4/28/08 to 4/29/08

NIDA program officers visited Mayo CTSA on 8/5/08 (met with faculty from 7 departments to discuss possible collaborative projects)

  • Duke CTSA PI, Robert Califf, visited and met with NIDA senior staff on 7/24/08
  • Communicated with Harvard CTSA PI, Lee Nadler, and CIO, John Halamka, on EMR 7/2/08 – 7/13/08

(many e-mail communications)

slide28

Collaboration with Mayo CTSAThrough Dr. Bob Rizza and Dr. David Warner

Mayo Health System PBRN

Linkages with Practice-Based

Research Network (PBRN)

(integrating addiction into

medical care settings, pain &

opioid addiction, nicotine addiction)

  • Potential research proposals
    • smoking,
    • chronic pain management
    • screening/brief intervention of SUD in

primary care, emergency care and trauma units

slide29

Numerous NIDA Interactions with CTSAs

  • Meeting with extramural investigators to assess opportunities for research on SUD in the CTSA (8/5/08 Mayo; 8/10/08 Duke)
  • Based on these recommendations NIDA is preparing a Program Announcement with set aside funds (PAS) targeting research within CTSA
  • Barbara Alving scheduled to speak about the CTSA to the Steering Committee of NIDA’s Clinical Trials Network on 10/21/08
  • NIDA NHSN annual meeting invited symposium on “Goals and Milestones of the NIH CTSA” (10/2/08)
slide30

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DBNBR

Wilson Compton, MD, MPE

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide31

Docked Dopamine and “Cocaine" in DAT

DAT Dopamine

DAT Cocaine

Beuming, T. et al., Nature Neuroscience, 11(7), pp. 780-789, 2008.

slide33

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Mary Affeldt

Associate Director for

Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Timothy Condon, PhD

Betty Tai, PhD

Mary Affeldt

Division of

Epidemiology,

Services &

Prevention Research

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DCNBR

Wilson Compton, MD, MPE

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide34

Brain Imaging Drug Use

Prevention Messages (R21)

(RFA-DA-07-007)

DCNBR & DESPR

16 Applications – 3 funded

  • Goals
  • To validate conceptual models of health communication by identifying
  • neural activation patterns in response to models driven drug-related
  • persuasive message stimuli
  • To discern differences in brain and cognitive processes that lead to
  • differential impact of media messages among populations of children,
  • adolescents, young adults, and parents varying by factors such as age,
  • gender, and propensity for risk-taking.
  • Required collaborative teams of brain imaging and prevention message
  • investigators
slide35

NIDA Blending Conference Evaluation Results

Over 1200 Participants Registered

slide36

NIDA Scholastic Addiction Science Award

At Intel International Science and Engineering Fair

  • World’s largest high school science fair
  • Only international student science fair representing all life sciences
  • 1500 finalists from 50 countries
  • More than one million students enter at local level
  • Yi-Han Su, 17, Taipei, China (chemistry)
  • Natalie Saranga Omattage, 17, USA MI. (bioengineering)
  • Sana Raoof, 17, USA NY (mathematics)
slide37

NIDA

NIDA Judges Review the Entries…2 Internal NIDA Staff & 2 NIDA Grantees

1500 entries screened

50 chosen for

consideration as

addiction-related or

deviant behavior-

related (based on

abstract titles)

8 or 9 interviewed

by all judges

simultaneously

top three selected

Cindy Miner, Ph.D.

Deputy Director, OSPC, NIDA

Genetics

Michael Kuhar, Ph.D.

Emory University

Pharmacology

Rochelle Schwartz-Bloom, Ph.D.

Duke University

Pharmacology

Ruben Baler, Ph.D.

OSPC, NIDA

Molecular Biology

slide38

The Novel Role of the GluCl α; Ion Channel & Diazepam Binding Genes in Alcohol Addiction

Kapil Vishveshwar Ramachandran – 16 – Austin, TX

Wild-type CS acquires behavioral tolerance

“Best of Category”

Cellular & Molecular

Biology Category at ISEF

Df-7589 is unable to acquire behavioral tolerance

slide39

Video Games:

The Next Generation's Addiction

Ethan Garrett Guinn – 17 – Moore, OK

385 participants

31% of all participants said that they had

reduced their amount of

schoolwork accomplished

because of video game use

16% of all participants said that they had

skipped meals

because of video game use

60% of all participants said that they have

gone to bed late

because of video game use

16% of all participants said that they have

spent less time with friends

because of video game use

29% of all participants said that they have

spent less time with their family

because of video game use

“Best of Fair”

2008 Oklahoma State

Science & Engineering Fair

slide40

What's In and What's Out:

High Schoolers' Perceptions of Coolness

Shelby Marie Raye – 14 – Bradenton, FL

American Psychological

Association Special Award

at ISEF (Third Place)

slide41

and encourage

schools to place more

emphasis on academic

achievements

How do we

get more kids

interested in

science??

Have them find

a topic they like

and build a project

around it.

Addiction Science Award Winners Visit NIH…

slide42

NIDA

NIDA Follow-Up

  • Information on winners sent to

Congressmen and Senators

  • Video clips of winners on NIDA’s Website
  • Invited winners to the Annual Meeting of

the Society for Neuroscience

Next Year:

  • Issue request for more projects using modeling or chemistry
  • Offer summer internships to work with scientists at IRP or with NIDA grantees